Osivax
Created in 2017
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
142 5,961Global tags
Activities
Technologies
Entity types
Location
70 Rue Saint-Jean-de-Dieu, 69007 Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 53
SIREN
829604750Engaged corporates
23
11 15Added in Motherbase
2 years, 6 months ago
biotech Value proposition
Pioneering A New Class of Universal Vaccines
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
biotechnology, immunology, antigens, vaccine, Influenza, universal, cellular immune response, CD8 T-cell, Infectious diseases, Immuno-oncology, and covidOriginal language
Pioneering A New Class of Universal Vaccines
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
HOME - Osivax
Osivax is developing a new class of universal vaccines empowering both arms of the immune system.
https://osivax.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 1 Apr 2023 | | |
 La French Tech Grand Paris French Tech, IT Services and IT Consulting | La French Tech Grand Paris French Tech, IT Services and IT Consulting | Other 27 Mar 2023 | | |
 La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | Other 17 Jul 2024 | | |
 La French Tech Lille French Tech, IT Services and IT Consulting | La French Tech Lille French Tech, IT Services and IT Consulting | Other 27 Mar 2023 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 27 Mar 2023 | | |
 numeum IT Services and IT Consulting | numeum IT Services and IT Consulting | Other 27 Mar 2023 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Other 29 Oct 2024 | | |
 Boston Consulting Group (BCG) Consulting, Business Consulting and Services | Boston Consulting Group (BCG) Consulting, Business Consulting and Services | Other 8 Mar 2023 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 21 Nov 2024 | | |
 GSK Pharmaceutical, Pharmaceutical Manufacturing | GSK Pharmaceutical, Pharmaceutical Manufacturing | Other 29 Nov 2022 | | |